Collaborations and Other Arrangements - Additional Information (Detail)		1 Months Ended				3 Months Ended	12 Months Ended
	May 30, 2020 USD ($) $ / shares shares	Oct. 31, 2023 USD ($)	Oct. 31, 2021 USD ($) shares	May 31, 2020 Targetcap Product	Apr. 30, 2016 USD ($)	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2024 USD ($) $ / shares	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Costs to obtain or fulfill contract capitalized							$ 0
Common stock, par value | $ / shares						$ 0.0001	$ 0.0001	$ 0.0001
Development Costs Pay Royalties			50.00%
Collaboration revenue							$ 57,877,000	$ 36,275,000	$ 52,121,000
Deferred revenue						$ 60,993,000	38,917,000	60,993,000	63,771,000
Collaboration term extension period	2024-04
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fee In Opt Pay			$ 20,000,000
Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fee In Opt Pay			$ 10,000,000
AvenCell Co Co Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue								6,600,000	11,400,000
Regeneron Pharmaceuticals Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Stock purchase agreement date	May 30, 2020
Aggregate transaction price remaining to be recognized							26,400,000
Deferred revenue						47,100,000	26,400,000	47,100,000
Transaction price allocated to combined performance obligation							51,700,000
Transaction price							51,700,000
Remaining transaction price transferred at inception of arrangement							11,400,000
Extension fee							30,000,000
Regeneron Pharmaceuticals Inc. [Member] | Related Party [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accounts receivable						35,700,000	7,200,000	35,700,000
Regeneron Pharmaceuticals Inc. [Member] | Hemophilia Co Co Agreements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue							11,700,000	10,700,000	10,400,000
Regeneron Pharmaceuticals Inc. [Member] | Regeneron Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue							21,900,000	19,600,000	11,900,000
Deferred revenue		$ 30,000,000
Collaboration agreement further option extension period		two years
Additional regeneron target cap | Targetcap				5
Number of unique ex vivo products commercialized | Product				10
Collaboration term extension period		2026-04
Regeneron Pharmaceuticals Inc. [Member] | 2016 Regeneron Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue additions							75,000,000
Collaboration revenue							20,700,000	11,700,000	22,500,000
Regeneron Pharmaceuticals Inc. [Member] | 2016 Regeneron Agreement [Member] | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments					$ 25,000,000
Regulatory based milestone payments under agreement					110,000,000
Sales based milestone payments under agreement					185,000,000
Regeneron Pharmaceuticals Inc. [Member] | Stock Purchase Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Purchase of common stock through private placement					$ 50,000,000
Regeneron Pharmaceuticals Inc. [Member] | 2020 Regeneron Amendment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue additions	$ 70,000,000
Fee to extend collaboration arrangement	$ 25,000,000
Regeneron Pharmaceuticals Inc. [Member] | 2020 Stock Purchase Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock shares sold | shares	925,218
Common stock, par value | $ / shares	$ 0.0001
Cash consideration received on sale of common stock	$ 30,000,000
Sale of stock, price per share | $ / shares	$ 32.42
Percentage of premium over volume-weighted average trading price of common stock during 30-day period prior to closing of equity transaction	100.00%
Regeneron Pharmaceuticals Inc. [Member] | 2024 Technology Collaboration Extension [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cumulative catch up adjustment						10,300,000	10,300,000
Amount allocated to licenses to targets and associated research activities and evaluation plans							48,300,000
Amount allocated to technology collaboration and associated research activities							3,400,000
Regeneron Pharmaceuticals Inc. [Member] | 2023 Regeneron Amendment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue							2,300,000	400,000
Sparing Vision [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration description			For product candidates the Company chooses to option, it will pay an opt-in fee between $10.0 million and $20.0 million depending on the stage of development of the target, reimburse certain costs, share in 50% of development costs and pay royalties to SparingVision on U.S. sales.
Collaboration revenue							2,500,000	1,800,000	200,000
Collaboration transaction price			$ 14,800,000
Deferred revenue						13,900,000	12,500,000	13,900,000
Development and commercial milestone payments							200,000,000
Sparing Vision [Member] | Related Party [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accounts receivable						500,000	600,000	500,000
Sparing Vision [Member] | Series A2 Preferred Stock [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Shares received in exchange of license | shares			83,316
ReCode Therapeutics, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and commercial milestone payments							262,000,000
AvenCell [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue							21,000,000	13,200,000	22,800,000
Accounts receivable						$ 0	0	0
AvenCell [Member] | Research Materials Shippmet Services [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue							0	0	0
AvenCell [Member] | AvenCell Co Co Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue							0	0	2,000,000
Kyverna Therapeutics Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue							0	0
Revenue									6,600,000
ONK Therapeutics [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue							$ 0	$ 0	$ 0